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Abstract
Introduction: Uveitis, or intraocular inflammatory disease, is a frequent extra-articular manifestation of several
forms of arthritis. Despite the frequent co-occurrence of uveitis and arthritis, little is understood of the eye’s
predisposition to this disease. We recently described a previously unreported uveitis in a murine model of
spondyloarthropathy triggered by autoimmunity to aggrecan, a prominent proteoglycan (PG) macromolecule in
cartilage. In contrast to the joint and spine, wherein interferon-gamma (IFNg) deficiency reduced disease, IFNg
deficiency worsened uveitis. Given the regulatory role of IFNg on the Th17 response and the current focus of anti-
interleukin-17 therapeutics in patients with uveitis and spondyloarthritis, we sought to determine the extent to
which interleukin (IL)-17 mediates uveitis in the absence of IFNg.
Methods: Antigen specific T cell cytokine production was measured in splenocyte cultures using multiplex-ELISA.
Transgenic (Tg) mice expressing the T cell receptor (TCR) recognizing the dominant arthritogenic epitope in the G1
domain of PG (TCR-Tg), also lacking IFNg, were immunized with PG. Mice were then systemically administered an
anti-IL-17 neutralizing antibody. The onset and severity of peripheral arthritis was evaluated by clinical scoring
criteria and histology. Uveitis was assessed using intravital videomicroscopy, which visualizes leukocyte trafficking
within the vasculature and tissue of the iris, and by histology.
Results: TCR-Tg splenocytes stimulated in vitro with recombinant G1 peptide demonstrated exacerbated
production of cytokines, such as macrophage inflammatory protein (MIP)-1a, MIP-1b, IL-1b, and most notably IL-
17A as a consequence of IFNg deficiency. In vivo, IL-17 inhibition prevented the component of PG-induced arthritis
that occurs independently of IFNg. Blockade of IL-17 ameliorated the ongoing leukocyte trafficking responses
within the iris vasculature and tissue, which coincided with reduced infiltration of leukocytes within the anterior
and posterior eye segments. However, the anti-IL-17 treatment resulted in unanticipated photoreceptor toxicity.
Conclusions: These data support a protective, regulatory role for IFNg in suppression of IL-17-mediated intraocular
disease and to a lesser extent, joint disease. The unanticipated photoreceptor toxicity raises some caution
regarding the use of anti-IL-17 therapeutics until the mechanism of this potential effect is determined.
Introduction
Uveitis, or intraocular inflammatory disease, is a leading
cause of visual loss and the most common, clinically
important extra-articular manifestation in several several
diseases such as ankylosing spondylitis (AS), Behçet’s
disease, and juvenile idiopathic arthritis. Anterior uveitis,
wherein the iris tissue is consistently affected, is the
most frequently diagnosed type of uveitis in North
America and Europe and occurs in as many as 50% of
patients with AS [1,2]. Despite the high incidence of
uveitis with AS and its closely related spondyloarthropa-
thies [3], the mechanism for their coexistence is not
known. Indeed, uveitis has not been a reported feature
in mouse models of arthritic disease.
We recently discovered that uveitis develops in a mur-
ine model of spondyloarthropathy that arises from auto-
immunity to the cartilage proteoglycan (PG) aggrecan
[4], which is a proposed potential autoantigen in AS [5].
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Experimental PG-induced uveitis appears to replicate to
some extent the spectrum of human uveitis that occurs
in patients with spondyloarthritis. In this mouse model,
disease is induced by immunization of genetically sus-
ceptible BALB/c mice with PG or its G1 domain [6]. A
progressive and chronic erosive polyarthritis and axial
spondylitis ensue [7-9]. PG-arthritis is a T cell-depen-
dent disease [10] in which the Th1 effector response
plays an important pathogenic role in the peripheral
joint disease [11,12]. Transgenic (Tg) mice expressing
the T cell receptor (TCR) recognizing an arthritogenic
epitope of PG (denoted here as TCR-Tg mice) develop
an earlier onset and more severe form of polyarthritis
than wild-type mice [13]. We previously reported an
unexpected discordant mechanism of disease in the eyes
versus joints with respect to interferon-gamma (IFNg) in
TCR-Tg mice. Mice deficient in IFNg develop exacer-
bated uveitis that is characterized by infiltrating granulo-
cytes, whereas the joint and axial disease are ameliorated
by IFNg deficiency [4].
The Th17 signaling axis has emerged as a potential
therapeutic target, and anti-IL-17 therapy is currently
under evaluation for spondyloarthritis and related dis-
eases, including psoriatic arthritis, psoriasis, inflamma-
tory bowel disease, Behçet’s disease and uveitis [14,15].
Given the counter-regulatory role for IFNg on the Th17
responses, the present study was designed to examine
whether the exacerbated uveitis that occurs in the
absence of IFNg results from an imbalance of the Th17
response. Here, we demonstrate that antigen-specific T
cell production of IL-17A is exacerbated in the absence
of IFNg. The worsened uveitis that occurs in IFNg KO
mice is inhibited by in vivo blockade of IL-17. The
remaining arthritis that ensues independently of IFNg is
further reduced as a consequence of IL-17 neutraliza-
tion. However, our findings reveal unanticipated photo-
receptor toxicity subsequent to the treatment with anti-
IL-17 antibody, in that the photoreceptors are frequently
obliterated. We conclude that IFNg exerts a critical reg-
ulatory role in suppression of IL-17, which is pathogenic
in uveitis. Our observations provide insight into a rela-
tively common but poorly understood eye disease and
could have potential dual clinical relevance as to how
we approach anti-IL-17 therapeutics in patients with
uveitis and spondyloarthritis.
Materials and methods
Mice, immunizations and treatment with anti-IL-17
antibody
TCR-Tg mice [13] that were backcrossed 10 generations
onto a BALB/c background were inter-crossed with
IFNg KO mice on BALB/c background (The Jackson
Laboratory, Bar Harbor, ME, USA); hereon abbreviated
GKO/TCR-Tg mice. Housing and experimentation on
mice was carried out under approval of the Oregon
Health and Science University Animal Care and Use
Guidelines. Female, 16-week-old mice were immunized
intraperitoneally (i.p.) with 100 μg purified human carti-
lage PG in 200 μl phosphate-buffered saline (PBS, pH
7.4) emulsified with dimethyl dioctadecyl ammonium
bromide (DDA; Sigma-Aldrich, St. Louis, MO, USA)),
along with 1.5 μg pertussis toxin (Sigma). Mice received
an additional i.p. injection of pertussis toxin 48 h later,
as previously described [4,16]. Control groups received
PBS/DDA and pertussis toxin injections without PG
antigen. For neutralization of IL-17, mice were adminis-
tered an i.p. injection of 100 μg of anti-IL-17 (anti-IL-
17A and IL-17A/F heterodimer; monoclonal rat IgG2a,
clone # 50104) blocking antibody or 100 μg of rat IgG2a
(isotype control antibody, IC; R&D Systems, Minneapo-
lis, MN, USA)) at the time of PG-immunization and
weekly thereafter. Mice were assessed weekly for clinical
manifestations of peripheral arthritis in a masked fash-
ion using an established scoring method as previously
described [4,16]. The scores ranged from 0 to 4 per paw
based on swelling, redness, deformities and ankylosis.
The data are represented as the cumulative score for all
four paws, resulting in a maximum of 16 per mouse.
Intravital videomicroscopy
Intraocular inflammation of the iris vasculature and tis-
sue in mice anesthetized with 1.7% isoflurane was video
recorded as previously described [4,17,18]. Digital videos
(10 sec each) of three independent regions of the iris
were captured with a black and white video camera
(Kappa Scientific, Gleichen, Germany) on an epifluores-
cence intravital microscope (modified Orthoplan; Leica,
Wetzlar, Germany). Diameter and length of each vessel
segment or iris tissue as well as leukocyte phenotype
(that is, rolling, adhering, infiltrating) were quantified
off-line using Image J analysis software available from
NIH.
Histopathology and uveitis scoring
Eyes and decalcified knee joints were fixed and prepared
for paraffin embedding, and 7 μm tissue sections were
stained with hematoxylin and eosin (H&E) as previously
reported [19,20]. For uveitis assessment, eyes were sec-
tioned through the pupillary-optic nerve axis at four dif-
ferent depths and three sections from each depth were
examined by a masked observer. Leukocyte infiltration
into the aqueous humor of the anterior segment and
vitreous body of the posterior segment was quantified as
the mean number of cells per section per eye. Struc-
tural, morphological and photoreceptor changes to the
retina were also assessed using an ocular histopathology
grading system, which is indicated as the “structural
score” [4]. Both eyes in each mouse were assessed.
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Antigen-specific in vitro splenocyte stimulation
Splenocytes collected from three individual TCR-Tg or
GKO/TCR-Tg mice were plated (2 × 106 cells/ml) in
96-well plates (BD Biosciences, San Diego, CA, USA) as
described [21], and cells were stimulated in quadrupli-
cate wells with 20 μg/ml of purified recombinant human
(rhG1) domain of aggrecan. Cytokines were measured in
supernatants 48 h post stimulation with Luminex multi-
plex ELISA (Millipore, Bedford, MA, USA). Data were
analyzed using BeadView Multiplex Analysis Software
(version 1.0, Upstate Cell Signaling Solutions, Lake Pla-
cid, NY, USA)).
Statistical analysis
Data are represented as mean ± SEM. Experiments were
reproduced at least twice. Means were compared and
statistical differences were determined with two-way and
one-way analysis of variance (ANOVA) with two-tailed,
Students t-test post hoc analyses. For the nonparametric
clinical arthritis scores and ocular histopathology scores,
the Mann-Whitney U test was used (Prism; Graph Pad
Software, La Jolla, CA, USA). Probability values < 0.05
were considered statistically significant.
Results
IFNg is an essential protective factor against uveitis
triggered by proteoglycan autoimmunity
As previously described [4], TCR-Tg mice lacking IFNg
(hereon abbreviated GKO/TCR-Tg) develop exacer-
bated uveitis, which is characterized by increased intra-
vascular cell trafficking responses within the iris,
increased glial activation and infiltration of granulo-
cytes. We initially examined the effects of IFNg defi-
ciency on cytokine production in vitro in response to
T cell stimulation with the arthritogenic G1 peptide of
PG (Figure 1). Enhanced production of cytokines, such
as the Th2-related eosinophilic cytokine, IL-5, as well
as higher production of neutrophil chemokines
(macrophage inflammatory protein (MIP)-1a and MIP-
1b) occurred as a consequence of IFNg-deficiency.
This observation is consistent with the histopathology
and predominance of neutrophils and eosinophils
observed in uveitic eyes as previously reported in mice
lacking IFNg [4]. IL-1b and most notably IL-17A pro-
duction were markedly enhanced, suggestive of a
heightened Th17 response in the absence of IFNg.
Negligible amounts of IL-23p40 or IL-23p19 were
detected (data not shown). The normally abundant
IFNg production (plotted on a separate axis, right
panel) was abolished in GKO/TCR-Tg mice as
expected. These data indicate that in the absence of
endogenous IFNg, IL-17 production is enhanced that
could in turn mediate uveitis.
PG-induced uveitis is dependent on IL-17 in the absence
of IFNg
Given the emerging data supporting a key role for IL-17
in patients with AS and related spondyloarthropathies
[22,23], we tested whether systemically administered
blocking antibody to IL-17 would alter the onset and/or
severity of uveitis occurring in the absence of IFNg.
Using intravital videomicroscopy, a technique that
Figure 1 IFNg-deficiency results in an altered cytokine profile including exacerbated IL-17A production. Antigen specific T cell cytokine
production was measured in splenocyte cultures from TCR-Tg mice with intact IFNg (WT) or TCR-Tg mice lacking IFNg (IFNg KO) that were
stimulated with the arthritogenic G1 peptide carrying the TCR-specific epitiope. Cytokine levels in the supernatants were quantified by multiplex-
ELISA (Luminex) at 48 h post stimulation. Data are the mean ± SEM of values combined from three independent experiments. * P < 0.05, ** P <
0.001, *** P < 0.0001 comparison between genotypes of G1-stimulated cells.
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allows us to visualize ongoing cellular trafficking
responses in vivo within the iris vasculature and tissue,
we examined ocular inflammation at three weeks post
immunization, which is a time previously established to
consistently coincide with uveitis in this model [4]. As
expected, mice that were immunized with adjuvant
alone showed negligible ocular inflammation regardless
of the antibody treatment (Figure 2A). In contrast, PG
immunization of mice treated with the isotype-matched
control antibody (IC) resulted in increased leukocyte
rolling and adherence within the microvasculature of
the iris (Figure 2A) and subsequent infiltration within
the iris tissue itself (as depicted in images captured by
intravital microscopy (Figure 2B). Neutralization of IL-
17 in the PG-immunized mice had a profound impact
on the cellular trafficking response, as all cellular
responses (rolling, adherence and infiltration) in the iris
were abolished.
Histopathological examination revealed a near-com-
plete absence of inflammation in both the anterior and
posterior eye segments as a consequence of anti-IL-17
therapy (Figure 3). In PG-immunized mice treated with
the isotype control antibody an increased presence of
infiltrated leukocytes within the aqueous humor, iris,
ciliary body, choroid and vitreous body is visualized (as
depicted in representative images Figure 3A). Consistent
with our prior report, retinal damage such as folding of
the inner nuclear layer (INL) and outer nuclear layer
(ONL) layers is also a pathological feature of uveitis in
mice lacking IFNg (Figure 3A), which is graded using a
structural scoring system [4]. In contrast, blockade of
IL-17 significantly diminished the number of cells in the
aqueous humor of the anterior segment as well as the
cells in the vitreous body of the posterior segment (Fig-
ure 3A, B). Likewise, IL-17 blockade abolished the ret-
inal vasculitis and retinal folding found in several IFNg-
deficient mice with PG-induced uveitis (Figure 3C).
Despite the abolishment of inflammatory changes in the
posterior segment upon IL-17 inhibition, a near-com-
plete ablation of the ONL and photoreceptor layer
(PRL) was observed in 9 of the 16 eyes examined (indi-
cated by brackets in Figure 3A). This damage would be
expected to result in complete vision loss. As indicated
by the brackets, there is a space where the ONL and
photoreceptor layers would normally be present, but
which are instead missing in PG-immunized mice trea-
ted with anti-IL-17A antibody. The depletion in these
layers could be a consequence of prior toxicity or cellu-
lar death, which may be attributed to these mice having
a higher disease structural score then most of the mice
Figure 2 Cellular trafficking responses exacerbated in the iris by IFNg deficiency areabrogated by IL-17A blockade. (A) Weekly i.p.
injections of anti-IL-17A blocking antibody or isotype-matched control antibody (IC) were administered into PG-immunized GKO/TCR-Tg mice.
Adjuvant-immunized control mice were also administered the anti-IL-17A blocking antibody and IC. The leukocyte trafficking response within the
iris was assessed by intravital microscopy at three weeks following PG-immunization. ** P < 0.001, *** P < 0.0001 comparison between
treatments: anti-IL-17 and IC antibodies (n = 8 mice/adjuvant groups and n = 12 mice/PG-immunized groups). (B) Representative images
captured by intravital videomicroscopy demonstrate the increased leukocyte infiltration within the iris tissue of PG-immunized, IC control mice,
which is completely blocked by anti-IL-17A treatment.
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that had received isotype-matched control antibody (Fig-
ure 3C). We also observed two eyes with similar retinal
toxicity in adjuvant-immunized mice that were treated
with anti-IL-17 antibody as indicated in the clinical
scores for structural changes (Figure 3C). These data
support a pathogenic role for IL-17 in uveitis; but PG-
induced inflammation also increases the susceptibility of
the eyes to the anti-IL-17-induced retinal toxicity.
IL-17 mediates arthritis in the absence of IFNg
PG-induced peripheral arthritis is considered to be pri-
marily a Th1 dependent disease that occurs indepen-
dently of IL-17 [11,24,25]. We have confirmed the
pathogenic role for IFNg in promoting peripheral arthri-
tis as well as axial disease in the TCR-Tg mice [4].
However, there is a precedent for IFNg regulating the
dependency of IL-17 in arthritis [26], and we demon-
strate here that the arthritis ensuing in the absence of
IFNg in TCR-Tg mice is mediated by IL-17. PG-induced
arthritis that was already attenuated by the absence of
IFNg was effectively prevented by anti-IL-17 (Figure
4A). The protective effects of IL-17 blockade observed
clinically were corroborated by histological changes (Fig-
ure 4B), wherein the synovial inflammation and infil-
trated leukocytes were reduced. These data support a
combinatorial role for Th1 and Th17 responses in pro-
moting arthritis while IFNg suppresses uveitis through
an IL-17-dependent mechanism.
Discussion
Our prior data demonstrated an important protective
role for IFNg in uveitis in a murine model of progressive
spondyloarthritis. Here, we tested the extent to which
IL-17 mediates uveitis occurring in the absence of IFNg.
Antigen-specific T cell production of IL-17A was exa-
cerbated in vitro as a consequence of IFNg deficiency.
Assessment of leukocyte trafficking within the iris
microvasculature and tissue by intravital videomicro-
scopy in mice treated with anti-IL-17 neutralizating
antibody revealed impaired intravascular responses, such
as rolling and adherence that coincided with fewer infil-
trating cells in the iris tissue. The histopathology
Figure 3 IL-17 inhibition prevents uveitis but results in photoreceptor toxicity. (A) PG-immunized GKO/TCR-Tg mice were administered
weekly i.p. injections of anti-IL-17A blocking antibody or isotype-matched control antibody (IC). Control mice were immunized with adjuvant
and the anti-IL-17A blocking antibody or IC. Histological assessment of uveitis was performed at three weeks post PG-immunization.
Representative images of the anterior and posterior eye segments are shown. Increased leukocyte infiltration in IC control mice is indicated by
arrows (two left panels) (H&E stain). The brackets on the far right panel (anti-IL-17 treated group) indicate the space where the ONL and
photoreceptor layers would normally be present, but which are absent. Original magnification: 200X. AC, anterior chamber; Co, cornea; CB, ciliary
body, Ir, iris; Li, limbus; Vi, vitreous, GCL, ganglion cell layer, INL, inner nuclear layer, ONL, outer nuclear layer, PRL, photoreceptor layer. (B) The
infiltrating cells present within the aqueous humor of the anterior eye segment or vitreous body of the posterior eye segment were quantified.
(C) Structural changes within the retina were scored in both eyes of each mouse. Data points represent individual eyes from each mouse. * P <
0.05 comparison between treatments: anti-IL-17A and IC antibodies (n = 7 mice/adjuvant groups; n = 9 mice/PG-immunized groups).
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demonstrated that IL-17 blockade significantly reduced
the number of infiltrating leukocytes within the aqueous
humor and vitreous body. The peripheral arthritis that
accompanies PG-induced uveitis was also diminished in
mice that received the anti-IL-17 blocking antibody.
However, despite protective effects of IL-17 inhibition
on PG-induced uveitis, unexpected retinal toxicity was
observed. Collectively, our data support an important
role for IL-17 in the pathogenesis of PG-induced uveitis,
which is negatively regulated by IFNg.
Uveitis encompasses a heterogeneous group of dis-
eases, and even though it can arise from microbial or
viral infection, it is frequently diagnosed in inflammatory
diseases involving the joints, such as ankylosing spondy-
litis, juvenile idiopathic arthritis, Behçet’s disease and
many others. The underlying mechanisms that result in
the co-existence of uveitis and arthritis/spondylitis are
poorly understood. An important association exists
between HLA-B27 and anterior uveitis in patients with
ankylosing spondylitis. Approximately 90% of affected
individuals have the inherited B27 allele [27], but HLA-
B27 does not account for all of the genetic risk for dis-
ease, nor the extent to which it influences the onset and
severity of uveitis versus spondyloarthritis. For example,
HLA-B27 transgenic rats spontaneously develop spondy-
loarthropathy but do not develop uveitis [28,29]. This
underscores the complexity of multisystem, immune-
mediated polygenic diseases, in which environmental
factors and/or endogenous microflora can contribute to
the pathogenesis of disease within the different target
organs.
Although it is not known whether the pathogenic
mechanisms in uveitis are the same as arthritis and/or
spondylitis, we initially hypothesized that the underlying
basic mechanisms would be shared between these two
organs in mice immunized with PG. Somewhat para-
doxically, however, we found that IFNg deficiency
reduced disease in the joint and spine but worsened dis-
ease in the eye [4]. The discordant effects of IFNg
underscore the complexity of how immune-mediated
diseases target multiple organs differentially. This phe-
nomenon has presented considerable challenges in the
treatment of uveitis in patients with multisystem dis-
eases, such as Behçet’s disease or AS. For example, the
TNFa inhibitor, etanercept, diminishes arthritic symp-
toms in a subgroup of patients with AS [30,31], but it
does not always have comparable beneficial effects for
uveitis in the same patients [32]; or it can even lead to
increased severity of uveitis [33]. Understanding the
unique aspects of individually affected tissues is clearly
pertinent to the design of optimal therapies.
The data presented here suggest that IFNg is protec-
tive in the eye by virtue of being counter-regulatory to
the IL-17 response. Studies with various KO mice or
blocking antibodies have dissected the separate roles of
Th1 and Th17 effector responses in the peripheral
arthritis aspect of the PG-induced disease model
[11,24,25], wherein IFNg serves an an important regula-
tory role in arthritis [26]. These studies indicate a domi-
nant pathogenic role for IFNg and the Th1 effector
response over that of the Th17 response in arthritis. We
recently demonstrated a similar pathogenic role for
IFNg in peripheral arthritis and extended its contribu-
tion to the axial disease that develops in TCR-Tg mice
[4]. Our findings would indicated that although the
Th17 response is not considered critical in the develop-
ment of PG-induced joint disease, it does appear to be a
prevailing response contributing to uveitis.
Th17 cells have been reported to play a role in induc-
tion of the animal model of posterior uveitis, experi-
mental autoimmune uveitis (EAU) [34] and have been
implicated in uveitis clinically [35,36]. IL-17 is thought
to contribute to disease through its ability to promote
recruitment and activation of neutrophils, which is con-
sistent with our previously reported increase in
Figure 4 IFNg regulates the requirement for IL-17 in PG-
induced arthritis. PG-immunized GKO/TCR-Tg mice were
administered weekly i.p. injections of anti-IL-17A blocking antibody
or isotype-matched control antibody (IC). Mice were also
immunized with adjuvant along with anti-IL-17A blocking antibody
and IC. The peripheral arthritis was assessed as a function of time.
(A) Clinical arthritic scores in GKO/TCR-Tg mice treated with anti-IL-
17A or IC; ** P < 0.001 comparison between anti-IL-17A and IC
antibody treatments in PG-immunized mice (n = 8 mice/adjuvant
groups and n = 12 mice/PG-immunized groups). (B) Representative
histological images of arthritic knee joints of GKO/TCR-Tg mice
treated with IC or anti-IL-17 at three weeks post immunization (F,
femur; T, tibia).
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granulocyte numbers in PG-immunized mice lacking
IFNg [4]. The production of IL-17 from T cells is well-
described, yet additional cellular sources including gδ T
cells, NKT cells, macrophages, mast cells and neutro-
phils may be just as important as the T cells [37-40].
Indeed, a recent report supports the role of innate
immune cells rather than T cells in expression of IL-17
in the joints of patients with spondyloarthritis [41].
Thus, the pathology of uveitis observed in response to
PG-immunization could involve coordinated events
between the T cells of the Th1 and Th17 lineages and
innate immune cells, which then propagate tissue
damage within uveitic eyes. Future studies that compare
the cytokine sources along with their targets within
uveitic eyes versus the arthritic joints will be
informative.
The IL-23/IL-17 axis is a major focus of spondyloar-
thritis research, and many pharmaceutical companies
are actively working on strategies to block IL-17 in uvei-
tis, AS and related spondyloarthropathies [14,15,36,42].
Therefore, it is critical to understand how this cytokine
can contribute to immune-mediated uveitis models in
mice, and possibly in humans. Although reduced clinical
signs of arthritis and ocular disease following anti-IL-17
treatment suggest great therapeutic potential for the use
of this antibody, our observations of retinal toxicity indi-
cate the need to proceed cautiously. We were unable to
measure visual acuity, however the observed depletion
of photoreceptors and ONL would be expected to result
in near to complete vision loss. This observation brings
to question why inhibition of IL-17 may result in toxi-
city within the eye. We are not aware of any reports
that demonstrate a role or involvement of IL-17A in the
survival of retinal cells. Nonetheless, a number of stu-
dies implicate IL-17A involvement in apoptotic or cell
survival responses in different cell types and diseases
[43-45], suggesting its potential role in cellular viability
within the eye. Retinal toxicity derived from anti-IL-17
antibody treatments has not been previously reported in
other murine uveitis models [34,46,47], indicating that
the toxicity could possibly involve a combination of
events within this particular disease model, such as glial
cell activation within the retina, the presence of PG-
antigen within the retina, and/or ongoing systemic dis-
ease [4]. At the time examined here (three weeks post
PG-immunization), the photoreceptor toxicity did not
coincide with increased expression of GFAP (glial fibril-
lary acidic protein, a marker of glial activation, data not
shown). However, we cannot rule out the contribution
of glial activation at times preceding photoreceptor toxi-
city. Studies are underway to elucidate whether inhibit-
ing the Th17 response through targeting IL-17R or the
upstream cytokine IL-23 reduces uveitis without photo-
receptor damage. These studies would inform us to the
potential toxicity effects of this particular antibody ver-
sus the contribution of the Th17 pathway in photore-
ceptor viability. The observations presented here yield
valuable information regarding contrasting mechanisms
of disease within different portions of the body and
could have an impact on how we approach therapy in
complex, inflammatory diseases.
Conclusions
The present study demonstrates an important regulatory
role for IFNg in uveitis associated with a murine model
of spondyloarthropathy. Antigen-specific activation of
naive TCR-Tg T cells lacking IFNg in culture resulted in
enhanced cytokine levels of IL-17A, which correlated
with worsened uveitis but not arthritis in PG-immu-
nized mice. Blockade of IL-17 in vivo ameliorated the
ongoing cell trafficking responses within the iris vascula-
ture and iris tissue, which coincided with diminished
leukocyte accumulation within the aqueous humor and
vitreous body. The residual arthritis ensuing in the
absence of IFNg was further reduced by anti-IL-17 neu-
tralization. These data support a combinatorial role for
Th1 and Th17 responses in arthritis, which is in opposi-
tion to the eye wherein we discovered a counter-regula-
tory role for Th1 and Th17 responses in uveitis. Despite
the beneficial anti-inflammatory effects of the anti-IL-17
blocking antibody, caution must be exercised in devel-
oping anti-IL-17 therapeutics for uveitis due to the
unexpected photoreceptor toxicity. Investigation of
simultaneous eye and joint disease within a mouse
could reveal important insights into how we approach
therapy in uveitic patients with inflammatory diseases
such as AS.
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